Paris-based techbio firm Generare has successfully closed a $23 million Series A funding round to advance its molecular discovery platform. The investment, co-led by Alven and Daphni with participation from existing investors, will enable the company to scale its efforts in decoding microbial genomes for novel drug candidates. This financing underscores growing confidence in data-driven approaches to overcome limitations in pharmaceutical research and development.
Tackling the Data Deficit in Drug Discovery
The modern drug discovery pipeline faces a significant data problem, where artificial intelligence models are often trained on recycled chemical information. This reliance on existing datasets limits the potential for discovering truly novel therapeutics and creates an innovation bottleneck. The challenge is not a lack of computational power but a scarcity of high-quality, diverse molecular data to fuel these advanced algorithms.
Generare addresses this challenge by exploring the vast, untapped chemical diversity encoded within microbial genomes. An estimated 97 percent of this molecular library, refined over three billion years of evolution, remains uncharacterized by science. This biological source has historically yielded landmark medicines, suggesting immense potential for future breakthroughs if it can be systematically accessed.
A Scalable Engine for Molecular Innovation
The company's platform integrates high-throughput cloning, sequencing, and synthetic biology to unlock this hidden chemistry at scale. It systematically screens tens of thousands of microbial genomes to identify gene sequences likely to produce bioactive compounds. These genes are then expressed to produce molecules whose structure and activity are characterized, creating a proprietary dataset.
This innovative approach has yielded significant results, with Generare reporting the characterization of over 200 previously unknown small molecules in 2025 alone. The company asserts this output is five times greater than the combined efforts of all other players in the field. These figures highlight the platform's capacity to rapidly expand the known chemical space for therapeutic development.
Fueling Growth and Expanding Partnerships
The $23 million in new capital will directly fund a major expansion of Generare's discovery capabilities and its unique molecular library. The company plans a tenfold scale-up of its platform, aiming to grow its dataset to over 2,000 novel compounds by 2027. This expansion is designed to meet increasing demand from partners in the pharmaceutical and agrochemical sectors.
To support this ambitious growth, Generare will also nearly double its multidisciplinary team of 25 scientists and engineers. The company is backed by prominent advisors, including former Novartis executive Dr. Frank Petersen, strengthening its scientific and strategic leadership. This investment in talent and technology positions Generare to compress decades of traditional discovery into just a few years.
This Series A financing marks a pivotal moment for Generare, validating its mission to solve the data scarcity problem in drug discovery. By systematically decoding nature's chemistry, the company is generating the novel inputs needed to unlock the full potential of AI in medicine. This work promises to open new frontiers for developing life-saving drugs and other bioactive compounds.